October 29th, 2025

Acuitas Therapeutics to Showcase LNP Delivery Platform at Four Prestigious Conferences in November 2025

Vancouver, B.C. – Acuitas Therapeutics, a global leader in lipid nanoparticle (LNP) delivery systems, today announced its participation in four upcoming conferences in November 2025. The company will present its latest advancements in LNP technology, highlighting its role in the development of next-generation therapeutic solutions, including vaccines and gene therapies, and underscoring its commitment to robust scientific validation.

"We're excited to share our latest research and connect with our colleagues around the world at these important events," said Dr. Ying Tam, Chief Scientific Officer of Acuitas Therapeutics. "Our participation in these conferences provides an excellent opportunity to showcase the versatility and potential of our LNP platform to fully enable mRNA-based medicines to address a wide range of diseases."

Conference Presentation Schedule:

1. Vaccines Research & Development — November 5-7, Boston, MA
    - Oral Presentation Title: Novel Lipids With Improved Activity For Prophylactic Vaccine Development
        - Presentation Time: November 6th, 2025
        - Presenter: Dr. Ghania Chikh, Sr. Director, Vaccine Development
    - Panel Presentation: Rapid Response Platforms for Outbreaks & Pandemic Preparedness
        - Presentation Time: November 5th, 2025
        - Presenter: Dr. Ghania Chikh, Sr. Director, Vaccine Development
    - Poster Presentation Title: Development of mRNA-LNP for Cancer Vaccine
        - Presentation Time: November 5th, 2025
        - Presenter: Dr. Fan Yan, Research Scientist II
2. mRNA Health Conference — November 11-13, Berlin, Germany
    - Oral Presentation Title: Next Generation Lipid Nanoparticles for Clinical Development of mRNA-based Therapeutics
        - Presentation Time: November 12th, 2025

        - Presenter: Dr. Ying Tam, Chief Scientific Officer

    - Poster Title: Effects of Body Weight and Anti-inflammatory Pre-medications and Concomitant Medication on the Pharmacodynamic Activity and Tolerability of mRNA-Lipid Nanoparticle Formulations in Monkeys
        - Presentation Time: November 11th, 2025
        - Presenter: Dr. Sherry Weppler, Sr. Research Scientist I

    - Poster Title: Development of mRNA-LNP for Cancer Vaccine
        - Presentation Time: November 11th, 2025
        - Presenter: Dr. Ghania Chikh, Sr. Director, Vaccine Development

    - Poster Title: Novel Lipids with Improved Activity For Prophylactic Vaccine Development
        - Presentation Time: November 12th, 2025
        - Presenter: Dr. Ghania Chikh, Sr. Director, Vaccine Development

Conference Attendance Schedule:

1. BIO Europe Fall — November 3-5, Vienna, Austria
2. Breakthroughs in Targeted *In Vivo* Gene Therapy — November 20-21, San Diego, CA

More information about these conferences is available at the organizers' websites. Acuitas' presented posters will be available on the presentations page after the respective conference concludes.

About Acuitas Therapeutics

Acuitas Therapeutics, Inc. is a Vancouver-based company focused on developing and optimizing lipid nanoparticle (LNP) delivery systems for nucleic acid based therapeutics. They collaborate with pharmaceutical and biotech companies, academic researchers, and global health organizations to advance a broad range of medicines for a variety of diseases.

Acuitas' clinically validated LNP technology has had a profound global impact – most notably enabling the Pfizer-BioNTech COVID-19 vaccine, **COMIRNATY®**, which has protected billions of people in more than 180 countries. The technology also enables **ONPATTRO®** by Alnylam Pharmaceuticals, the first FDA-approved RNAi therapeutic for treating the rare and fatal disease transthyretin amyloidosis. More recently, Acuitas' LNP technology has delivered other

groundbreaking firsts: the **first in-human proof of concept** for genome base editing and the **first personalized CRISPR therapy**.

Today, they are advancing next-generation LNP to support a variety of therapeutic modalities. This includes targeted LNP for extrahepatic and *in vivo* CAR-T cell therapies, epigenetic medicines to modulate gene expression without altering DNA, multivalent vaccines for infectious diseases — such as malaria, HIV/AIDS, and tuberculosis — as well as oncology vaccines, including personalized cancer vaccines.

For more information, visit www.acuitastx.com.

-END-

Media Contact:
Jakub Cikowski
HDMZ
acuitas.pr@hdmz.com